Reimbursement Challenges and Solutions with Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Ken Schaecher, MD, Medical Director of SelectHealth, describes in his opinion how there is no payer coverage issues with patients with polycythemia vera at this time. Supported through funding from Incyte
How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients
Dr David Spigel discusses how medical oncologists and the rest of the cancer care team can best communicate with pathologists to help make informed treatment decisions for individual patients and set up new assays for emerging biomarkers as they are discovered.